$13.26 0.41 (+3.19%)
2/13/2012 4:02 PM

Elan Corp, plc (ADR) (NYSE:ELN)

CAPS Rating: 4 out of 5

The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

Recs

0
Player Avatar bermudatrader (20.20) Submitted: 1/26/2008 4:18:14 PM : Outperform Start Price: $22.42 ELN Score: -46.71

Solid alzheimers pipeline and the best MS drug on the market.

Phase II results for AAb-001 come out this spring/summer, good data will propel this stock to the $40's.

Report this Post Add Comment

Featured Broker Partners


Advertisement